Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years. The outlook for global spending on medicines has become clearer as the traumas recede and uncertainties give way to more predictable challenges. Policymakers across developed and emerging economies are shifting from crisis to rebuilding modes with a focus on longer-term issues of sustainability. Complex trade-offs remain, and improved efficiency and quality of healthcare informed by evidence-based decision-making will inform the critical decisions in the coming decade.
The largest driver of medicine spending through the next five years is still expected to be global COVID-19 vaccinations, but leaving aside the pandemic, global spending on medicines continues to be driven by innovation and offset by losses of exclusivity and the lower costs of generics and biosimilars.
In this report, we quantify the impact of these dynamics and examine the spending and usage of medicines in 2022 and the outlook to 2027, globally and for specific therapy areas and countries. We intend for this report to provide a foundation for meaningful discussion about the value, cost, and role of medicines over the next five years in the context of overall healthcare spending.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.